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Background: Toxoplasma encephalitis is caused by the opportunistic protozoan parasite Toxoplasma gondii. Primary
infection with T. gondii in immunocompetent individuals remains largely asymptomatic. In contrast, in
immunocompromised individuals, reactivation of the parasite results in severe complications and mortality. Molecular
changes at the protein level in the host central nervous system and proteins associated with pathogenesis of toxoplasma
encephalitis are largely unexplored. We used a global quantitative proteomic strategy to identify differentially regulated
proteins and affected molecular networks in the human host during T. gondii infection with HIV co-infection.
Results: We identified 3,496 proteins out of which 607 proteins were differentially expressed (≥1.5-fold) when frontal lobe
of the brain from patients diagnosed with toxoplasma encephalitis was compared to control brain tissues. We validated
differential expression of 3 proteins through immunohistochemistry, which was confirmed to be consistent with mass
spectrometry analysis. Pathway analysis of differentially expressed proteins indicated deregulation of several pathways
involved in antigen processing, immune response, neuronal growth, neurotransmitter transport and energy metabolism.
Conclusions: Global quantitative proteomic approach adopted in this study generated a comparative proteome profile of
brain tissues from toxoplasma encephalitis patients co-infected with HIV. Differentially expressed proteins include previously
reported and several new proteins in the context of T. gondii and HIV infection, which can be further investigated. Molecular
pathways identified to be associated with the disease should enhance our understanding of pathogenesis in toxoplasma
encephalitis.
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Toxoplasma encephalitis (TE) is a major complication of
central nervous system caused by Toxoplasma gondii, an
obligate intracellular protozoan. TE presents with highly
varied neurological symptoms with both focal and diffuse
neurological abnormalities. The risk of developing TE is
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unless otherwise stated.with HIV infection, solid organ transplantation and those
receiving immunosuppressive therapy, mostly due to recru-
descence of latent infection [1-3].
Various diagnostic tests have been in practice for the
diagnosis of toxoplasmosis in serum, CSF and brain
tissues [3]. Conventionally, radiologic techniques such as
CT scan and MRI scan are used for visualizing the lesions
produced in TE [4]. Enzyme-linked immunosorbent
assays to measure IgG and IgM levels against T. gondii in
serum and urine are also routinely used in diagnostics [5].
Advanced diagnostic procedures including loop mediated
isothermal amplification reactions and PCR-based assays
are also used for the detection of T. gondii with a high
degree of sensitivity [6].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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asexual phases. Sexual reproduction occurs in cats, which
are the definitive hosts for this parasite. Gametocytes
present in the intestinal epithelium of cats are fertilized
and infectious oocysts are shed through feces. These
oocysts sporulate in the environment and contaminate
soil, water and food, through which infection is trans-
mitted to warm blooded animals including humans.
These warm blooded animals act as intermediate hosts, in
which asexual reproduction occurs in the form of actively
replicating tachyzoites. Host immune response induces
conversion of tachyzoites to semi-dormant bradyzoites,
which form tissue cysts. The life cycle of T. gondii is com-
pleted when tissue cysts are ingested again by cats [7].
Around one-third of the general population worldwide
is considered to be infected with T. gondii, most of whom
are asymptomatic [7]. The prevalence of infection depends
on the climatic conditions and the age of the population.
Studies in India have shown that ~25% of general popula-
tion is seropositive for T. gondii IgG antibodies [3].
Transmission of T. gondii to humans may occur from
an infected mother to the fetus or orally by consump-
tion of either sporulated oocysts from contaminated
soil, food or water or bradyzoites from undercooked or
uncooked meat. Upon gaining entry into the human
body,T. gondii gets converted into tachyzoite stage, crosses
the gastrointestinal barrier to disseminate throughout the
body including immune privileged sites such as brain, ret-
ina and fetus. Tachyzoites invade the astrocytes and micro-
glial cells to breach the blood-brain barrier and form tissue
cysts in the brain [8]. In immunocompromised individuals
with <200 CD4+ cells per μl, the conversion of bradyzoites
to tachyzoites leads to TE [1].
During acute infection and reactivation of latent T. gondii
infection, the immune system challenges the parasite by
producing interferon gamma (IFN-γ), tumor necrosis factor
alpha (TNF-α) and inducible nitric oxide synthase (iNOS).
CD4+ T cells, CD8+ T cells and natural killer cells produce
IFN-γ and TNF-α following T. gondii infection. IL-12, IL-6
and IL-4 also were shown to prevent formation of cysts
and tachyzoite proliferation, probably through the mainten-
ance of IFN-γ and TNF-α mediated resistance [9]. IFN- γ
also induces the expression of vascular cell adhesion
molecule-1 (VCAM-1), which enhances the recruitment of
CD4+ T cells and CD8+ T cells to the site of infection [10].
Molecular mechanisms underlying the host-pathogen inter-
actions have been studied using mouse models and cell
lines with respect to TE. Though substantial information
was provided by these studies, there still remain un-
answered questions that emphasize the need for fur-
ther studies at the molecular level in humans [11,12].
Therefore, we carried out a global unbiased quantitative
proteomic analysis of brain tissues from TE patients
co-infected with HIV by iTRAQ labeling and high-resolution mass spectrometry using LTQ-Orbitrap Velos
mass spectrometer. Differentially expressed proteins iden-
tified from TE brain tissues co-infected with HIV included
several novel proteins along with a few proteins, which
were reported earlier. We also validated three differentially
expressed proteins using immunohistochemistry (IHC)
and found that their expression was consistent with
the mass spectrometry results.
Results and discussion
We carried out a quantitative proteomic analysis of the
frontal lobe brain tissues from TE patients co-infected
with HIV and uninfected control subjects using iTRAQ
labeling followed by SCX fractionation and high reso-
lution Fourier transform mass spectrometry. The mass
spectra were searched using SEQUEST search algorithm
against Human RefSeq protein database version 52, which
comprised of 33,987 protein sequences. In total, we
identified 3,496 proteins of which 607 proteins were
differentially expressed (≥1.5-fold). Among the differ-
entially expressed proteins, 293 and 314 proteins were
found to be overexpressed and downregulated, respect-
ively, in brain tissues of TE patients in comparison to
control brain tissues (Additional file 1: Table S1). A
partial list of overexpressed and downregulated proteins is
provided in Tables 1 and 2, respectively. Representative
MS/MS spectra of selected proteins are provided in
Figure 1. We have deposited the mass spectrometry data
to Human Proteinpedia and PRIDE repositories [13,14].
Categorization of differentially expressed proteins based
on Gene Ontology annotation
We categorized differentially expressed proteins based
on their biological processes and molecular function
using annotations in Human Protein Reference Data-
base (HPRD; http://www.hprd.org) [15,16], which fol-
lows Gene Ontology (GO) standards. Proteins involved
in important biological processes such as cell communica-
tion (23%), metabolism/energy pathways (14%), transport
(13%), cell growth/ maintenance (10%) and immune
response (5%) were found to be altered in response to TE
co-infected with HIV (Figure 2A). Classification of dif-
ferentially expressed proteins based on their molecular
functions enriched for proteins with catalytic activity
(5%), transporter activity (9%), GTPase activity (5%),
and cell adhesion activity (4%) (Figure 2B).
Functional annotation of differentially expressed proteins
in toxoplasma encephalitis
Pathway analysis of the differentially expressed proteins
in TE co-infected with HIV brain tissue samples using
the Pathway Architect module in GeneSpring (version
12.6) revealed the enrichment of several proteins involved
in pathways such as neural transmission across chemical
Table 1 A partial list of upregulated regulated proteins in toxoplasma encephalitis
Gene symbol Protein Description Toxoplasma encephalitis/Control
(Fold change)
1 HLAB Major histocompatibility
complex, class I, B
It is a membrane protein and a member of HLA
complex. It plays an important role in immune
system by presenting antigens derived from
endoplasmic reticulum.
4.4
2 MPO Myeloperoxidase It is a heme protein, expressed mainly in azurophilic
granules of neutrophils. It produces hypohalous acid
involved in killing of bacteria and pathogens.
3.8
3 SERPINA1 Alpha-1 antitrypsin It is a member of serpin family. It acts as anti-trypsin
inhibitor and its targets mainly include protein like
elastase and chymotrysin
2.9
4 CRP C-reactive protein It belongs to pentraxin family. It is involved in a wide range
of host related immune response reactions.
2.3
5 ICAM-1 Intercellular adhesion
molecule 1
It is a glycoprotein, which acts as an intercellular adhesion
molecule and is involved in pro-inflammatory pathways.
2.1
6 GRIA3 Glutamate receptor
3 isoform 1
It is a neurotransmitter receptor, which regulates
neurophysiological process by acting as an excitatory
neurotransmitter.
2.0
7 CACNG2 Voltage-dependent calcium
channel gamma-2 subunit
It is an integral membrane protein, which mediates
trafficking of AMPA receptor.
1.7
8 SYT1 Synaptotagmin-1 It is an integral membrane protein. It is involved in sensing
of Ca2(+) during the process of vesicular trafficking and
exocytosis.
1.8
9 STXBP1 Syntaxin-binding protein 1 It plays a significant role in neurotransmission and
modulation of synaptic vesicle trafficking.
1.6
10 SYN1 Synapsin-1 It is a phosphoprotein involved in the inhibition of
neurotransmission and regulation of synaptogenesis.
1.6
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ing and presentation along with complement and coagula-
tion cascade pathway. In addition, several key modulators
of the brain-derived neurotrophic factor (BDNF) signaling
pathway were found to be differentially regulated, includ-
ing aldo-keto reductase (AKR1C1), alkaline phosphatase
(ALPL), secreted phosphoprotein (SPP1), heat shock pro-
tein (HSPA1A), chromogranin B (CHGB), ras homolog
family member (RHOG), regulating synaptic membrane
exocytosis (RIMS3), inositol polyphosphate-1-phosphatase
(INPP1), integrin, alpha 2 (ITGA2), filamin C (FLNC) and
polymerase I transcript release factor (PTRF) [17]. RHOG,
which was found to be downregulated in TE compared to
control tissues, is involved in mediating BDNF-induced
neurite outgrowth [18]. It has been reported that HIV-1
promotes neuronal injury by reducing the length of neur-
onal processes through reduction in the mature BDNF
levels in neurons [19]. Therefore, differential expres-
sion of several important molecules in BDNF signaling
pathway may be the cause of cognitive aberration in
HIV-associated TE (Figure 3).
Biological significance of the differentially expressed
human proteins
Differentially expressed proteins identified in the current
study covers a diverse spectrum of functions includingtransmission across chemical synapses, antigen processing
and presenting, neurotransmitter release cycle and interferon
signaling. We identified proteins including guanine nucleo-
tide binding protein (GNAO1), major histocompatibility
complex class II protein (HLA-DRB1), heat shock 70 kDa
protein 1A/1B, extracellular protein laminin (LAMA2),
signal transducer and activation of transcription (STAT1),
which have been previously reported to be associated with
TE among the upregulated proteins. Calcium signaling by
multiple G–protein effectors has been reported to be altered
by inflammatory mediators, in inflammatory conditions in
central nervous system (CNS) including infection, trauma,
stroke, neurodegeneration and autoimmunity [20]. HLA-
DRB1 is known to be a risk factor in HIV-1 patients for
developing opportunistic infections, especially TE [21]. In
addition, heat shock 70 kDa protein (HSPA1B) polymorph-
ism has been shown to be associated with risk for schizo-
phrenia, positive symptoms as well as clinical outcome
[22,23]. LAMA2 is an extracellular matrix protein, which
regulates and promotes oligodendrocyte development,
whereas STAT1 is actively modulated by T. gondii increas-
ing the likelihood of its survival within the host [24-26].
Host immune response proteins
Among the differentially expressed proteins, those in-
volved in host immune response, such as complement
Table 2 A partial list of downregulated regulated proteins in toxoplasma encephalitis
Gene
symbol
Protein Description Control/Toxoplasma encephalitis
(Fold change)
1 ASPA Aspartoacylase It catalyzes the hydrolysis of N-acetyl aspartate (NAA)
to form aspartate and acetate. Accumulation of NAA
due to deficiency of ASPA results in seizures and loss
of previously acquired skills.
3.7
2 PLP1 Myelin proteolipid protein It is a transmembrane proteolipid protein, which
synthesizes and/or maintains multi lamellar
structure of myelin.
3.4
3 RHOG Rho-related GTP-binding protein,
member G
It belongs to RHO family of small GTPase superfamily.
It has a role in cytoskeleton arrangement and various
Rho and Rac mediated signal transduction.
2.7
4 CBR1 Carbonyl reductase1 It is a monomeric enzyme, which metabolizes toxic
environmental quinones and pharmacological




It has a major role in NADH oxidation, gluconeogenesis,
triglyceride biosynthetic process and various other
metabolic pathways.
2.4
6 VAT1 Synaptic vesicle membrane protein
VAT-1
It belongs to quinone oxidoreductase subfamily under
the family named zinc-containing alcohol dehydrogenase
proteins. It inhibits mitochondrial fusion by acting along
with mitofusin proteins.
2.3
7 RAP1A Ras-related protein Rap-1A It is a member of the Ras family of small GTPases, which
is known to regulate cell-cell adhesion. Depletion of RAP1
is shown to increase endothelial permeability.
2.2
8 HSPA2 Heat shock-related 70 kDa protein
2
It belongs to heat shock protein 70 family. It has a role
in synaptonemal complex disassembly.
2.2
9 PRKAR1A cAMP-dependent protein kinase
type I-alpha regulatory subunit
It belongs to cAMP-dependent kinase regulatory chain
family having role in mesoderm formation, blood
coagulation and various signal transduction pathways.
2.1
10 CRYL1 Lambda-crystallin homolog It belongs to the family of oxidoreductase. It has a role
in fatty acid metabolism.
1.7
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tified in this study. We detected several proteins reported
in interferon-gamma signaling to be overexpressed, includ-
ing guanylate binding protein (GBP1), major histocompati-
bility complex protein (HLA-B), intercellular adhesion
molecule (ICAM1), ubiquitin-like modifier (ISG15) and
STAT1. Microtubule-associated protein tau (MAPT),
C-reactive protein (CRP) along with STAT1, involved
in IL-2, IL-5 and IL-6 signaling pathways, were also
found to be overexpressed in TE brain tissues. In
patients with T. gondii and HIV infection, marked
decrease in CD4+ T cells has been reported and often
there is no significant increase in the antibody titer, as
observed during aggravation of infection [27]. Further-
more, in T cells from HIV patients with toxoplasmosis,
secretion of both interferon-gamma and IL-2 has been
known to be altered [28]. Persistence of toxoplasma in-
fection is contributed by aberrant production of these
vital immune cytokines. Therefore, with the progres-
sive depletion of the T cell dependent protective mech-
anisms in HIV-1, especially CD8+ T cells, probability
of developing toxoplasma infection increases. However,
in our study we observed overexpression of proteinsassociated with interferon-gamma and IL-2 signaling
pathways, indicating restored immune response in the
patients. Similar restoration of immune response has
been reported by other studies in patients previously
subjected to antiretroviral therapy [29,30].
Other proteins involved in interferon signaling that were
found to be overexpressed include beta-2 microglobulin
(B2M), major histocompatibility complex protein (HLA-G),
interferon-induced protein with tetratricopeptide repeats
(IFIT1 and IFIT3) and myxovirus (influenza virus) resist-
ance 1 interferon-inducible protein (MX1). B2M is import-
ant in diagnosis of HIV and its rise in HIV patients is
considered as an indicator of HIV progression [31]. In-
creased HLA-G level is known to be associated with
congenital transmission of T. gondii whereas, increased
expression of IFIT1 has been reported in HIV-1 infected
astrocytes [32,33]. Overexpression of B2M, IFIT3, MX1
and STAT1 has been reported in the brains of neuro-
AIDS patients, including those on combination antiretro-
viral therapy and also in non-human primate model of
neuro-AIDS [34]. JAK/STAT pathway is known to be
modulated by toxoplasma and involved in the pathogen-
esis of depression [35,36]. It has also been shown that
m/z
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Figure 1 Representative MS/MS spectra of peptides of differentially expressed proteins: A) Major histocompatibility complex, class I, B
(HLA-B) protein is upregulated 4.4-fold in toxoplasma encephalitis brain tissues when compared to controls. B) Alpha-1 antitrypsin
(SERPINA1) protein is upregulated by 3.0-fold in toxoplasma encephalitis brain tissues when compared with control. C) Ras homolog family member
G (RHOG) protein is downregulated by 2.5-fold in toxoplasma encephalitis brain tissues when compared with control. D) CD9 molecule (CD9) is
downregulated by 2.0-fold in toxoplasma encephalitis brain tissues when compared with control.
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other psychiatric manifestations [37].
Proteins in neurotransmitter release cycle and
transmission across chemical synapses
In this study, several proteins playing an important
role in neurotransmitter release cycle and transmission
across chemical synapses were found to be differen-
tially expressed. These include actin (ACTN2), calcium
channel voltage-dependent gamma subunit 2 (CACNG2),
DnaJ protein homolog (DNAJC5), gamma-aminobutyric acid
receptors (GABBR1, GABBR2, GABRA1 and GABRG2),
guanine nucleotide binding proteins (GNG13 and GNG4),
glutamate receptors (GRIA3 and GRIN1), monoamine oxi-
dase A (MAOA), member RAS oncogene family (RAB3A),
solute carrier family proteins (SLC17A7, SLC32A1 and
SLC6A1), syntaxins (STX1A and STXBP1), synapsins
(SYN1, SYN2 and SYN3) and synaptotagmin (SYT1).
Among these, CACNG2 has been reported to be asso-
ciated with schizophrenia [38,39]. DNAJC5 anchored
to synaptic vesicles, along with exocrine, endocrine and
neuroendocrine secretory granules, has been shown to have
anti-neurodegenerative properties [40]. Interestingly, evi-
dence of GABAergic dysfunction in lateral cerebella, due to
reduced protein levels of both receptors GABBR1 and
GABBR2, has been reported in subjects of schizophrenia,bipolar disorder and major depression [41]. Also, it has
been shown that mutations in GABRA1 lead to epileptic
encephalopathies and mutations in GABRG2 have been
associated with generalized epilepsy [42-44]. Among over-
expressed, glutamate receptors GRIA3 has a positive asso-
ciation in women patients with schizophrenia patients
[45]. MAOA is known to catalyze the oxidative de-
amination of amines and has been implicated in anti-
social behavior [46]. Alterations in solute carrier family
proteins (SLC17A7, SLC32A1 and SLC6A1) implicat-
ing impairment of synaptic transmission may contrib-
ute in schizophrenia pathology [47]. Among syntaxin
proteins (STX1A and STXBP1), STXBP1 was known
to be a key molecule in ion channel regulation and
synaptic exocytosis and has been reported widely in
cases of migraine in different geographical settings
[48]. Mutations in STXBP1 gene are responsible for
infantile epileptic encephalopathy-4 [49,50]. SYN1 gene
has been reported as a susceptible gene for autism-
spectrum disorder (ASD). Knockout mice study re-
vealed that lack of Syn1, Syn2 and Syn3 cause cognitive
impairment and activates strong epileptic phenotype in
mice (Syn1 and/or Syn2) [51]. Synaptotagmin-1 (SYT1)
triggers neurotransmitter release at synapse by binding to
calcium (Ca2+) [52]. Therefore, differential expression of















































Figure 2 Gene Ontology (GO) analysis of differentially regulated proteins: A) Biological processes-based analysis showed majority of
the proteins involved in processes such as cell communication, growth and transport. B) Molecular function-based analysis revealed a
majority of the proteins with unknown functions. However, a significant number were seen with transporter and catalytic activities among others.
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from TE infection to seizure activity and cognitive im-
pairments. Moreover, a number of studies connect T.
gondii with higher incidence of schizophrenia [53,54].
Validation of differentially expressed proteins by
immunohistochemistry
Differentially expressed proteins identified using high
resolution mass spectrometry from frontal lobe tissues
of TE were validated using IHC. For this, we selected
three candidates - HLA-B, SERPINA1 and RHOG - forIHC validation based on the molecular function of the
proteins and its significance to the disease manifestation
(Figure 4).
Major histocompatibility complex, class I (HLA-B)
HLA-B protein known to be present on surface of nucle-
ated cells is involved in antigen presentation to cytotoxic
T cells. Earlier studies have shown that infection with
T. gondii elicits HLA-B expression in dendritic cells,
astrocytes and macrophages [55]. Toxoplasma antigens





Figure 3 Biological network analysis of differentially expressed proteins using GeneSpring identified deregulated BDNF pathway: Nineteen
proteins involved in the BDNF pathway were differentially expressed including the downregulation of the BDNF receptor protein – NTRK2.
Proteins involved in BDNF mediated lamellipodia formation and neurite outgrowth were downregulated whereas proteins involved in BDNF mediated
synaptic plasticity were overexpressed.
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gen presentation evoking active immune response [56].
We found upregulation of HLA-B in HIV-associated
TE brain tissues. Immunohistochemical staining showed
strong HLA-B expression in histiocytic elements of toxo-
plasma lesion, while the pale zones represent the necrotic
acellular zones. Strong expression of HLA-B was observed
in the perivascular histiocytes at higher magnification.
Alpha-1 antitrypsin (SERPINA1)
Alpha-1 antitrypsin (SERPINA1) is a member of the ser-
pin family. Polymorphisms in the SERPINA1 gene have
been reported to be associated with fibromyalgia and
mood disorders [57]. Hypersialylated SERPINA1 has been
reported to be a protein of significant diagnostic value for
early detection of Parkinson’s dementia [58]. It has also
been associated with other neurological disorders like Alz-
heimer’s disease and schizophrenia [59,60]. It is interesting
to note that serine protease inhibitor neuroserpin regu-
lates the growth and maturation of hippocampal neurons
[61] dysfunction of hippocampus is one of the criticalfactors in the pathogenesis of schizophrenia [62]. Apart
from this alpha-1 antitrypsin blocks the processing of
group antigens (Gag) and envelop proteins (Env), which
results in suppression of HIV-1 morphogenesis [63]. Im-
munohistochemical labeling showed strongly expressed
alpha-1 antitrypsin in the glial cells, the micro vessels and
histiocytes of toxoplasma encephalitis brain tissues unlike
in the control brain tissues, which showed low expression
in glial cells and the necrotic vessel wall.
Ras homolog family member G (RHOG)
RHOG is mainly involved in actin cytoskeleton re-
arrangement, cell migration and protection of cell from
anoikis [64,65]. Recent studies unraveled the role of RHOG
in pathogenesis of bacterial infections [66]. It has been de-
tected in rat hippocampus, cerebellum and specific expres-
sion was observed in oligodendrocytes and neuronal cells
of brain [67,68]. As reported by multiple studies RHOG
has significant role in various neurological processes in-
cluding neurite extension, spine morphogenesis, neuronal
progenitor cell proliferation and axonal outgrowth [69,70].
Figure 4 Immunohistochemistry-based validation of differentially expressed proteins in toxoplasma encephalitis co-infected with HIV:
A) Histiocytic elements in the toxoplasma lesion strongly expressed HLA-B, while the pale zones represent the necrotic acellular zones,
B) Higher magnification highlights strong expression of HLA-B in the perivascular histiocytes, C) The expression of RHOG is marginally
downregulated in the histiocytes and newly formed capillary endothelia, D) Control brain has low expression of alpha-1 antitrypsin
(SERPINA1) in glial cells and a necrotic vessel wall, E) In the case of toxoplasma encephalitis the glial cells, the micro vessels and histiocytes
expressed alpha-1 antitrypsin strongly unlike the control.
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sues co-infected with HIV. Immunohistochemical labeling
showed the marginal downregulation of RHOG expression
in the histiocytes and newly formed capillary endothelia.
Conclusions
TE is a principal opportunistic infection of the CNS in
individuals infected with HIV. The molecular profile asso-
ciated with pathological progression of TE has not been
explored using a global proteomics platform. Utilizing an
iTRAQ-based quantitative proteomic approach, we identi-
fied a subset of proteins, which are differentially expressed
in TE co-infected with HIV brain tissues. Our data pro-
vides insights into molecular profiles of TE, which can be
investigated through several hypotheses. We found differ-
ential regulation of key proteins involved in host-immune
response and neurotransmitter release cycle, neuronal
growth, energy metabolism and calcium transport. In-
crease in the neurotransmission across synapses may pre-
dispose the patients to seizure activity and cognitive
impairment in the clinical evolution of TE. We also identi-
fied overexpression of proteins, which may have a role inthe development of schizophrenia among TE patients.
Upregulation of caveolar proteins and intercellular
adhesion molecules indicate their possible role along with
gp41 protein from HIV in mediating the entry of the path-
ogens by breaching blood-brain barrier.
Methods
Sample collection
The study was approved by scientific ethics committee of
National Institute of Mental Health and Neuro Sciences
(NIMHANS), Bangalore, India. Brain tissue samples from
the lesion site within the frontal lobe from five confirmed
cases of cerebral toxoplasmosis associated with HIV-1
infection were collected during autopsy and divided into
symmetric halves. One half was processed for histopatho-
logical studies including immunohistochemistry for
toxoplasma and macrophage response (CD 68), while the
other half was used for proteomic study. All tissues
included in the study revealed features of toxoplasma
encephalitis in the cortical ribbon and subcortical zone
with areas of necrosis, inflammation and variable CD
68 positive histocytic response along with the presence
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zoites). All cases were positive for HIV-1 on serological
testing and confirmed to be HIV-1 clade C by clade
specific PCR developed at Jawaharlal Nehru Centre for
Advanced Scientific Research in Bangalore and validated.
Five uninfected control brain tissues from the similar age
and sex group were collected from victims of road traffic
accidents within 10-19 h post mortem during autopsy
(Additional file 2: Tables S2 and S3). Fifteen toxoplasma
encephalitis frontal cortex brain tissue samples including
five samples taken for proteomics study from age group 1
to 54 years and one uninfected control sample were in-
cluded for immunohistochemistry validation. The autopsy
was conducted within 3-19 hours and bodies were kept at
4°C after death. The control tissues were confirmed to be
negative for HIV-1 and toxoplasma infection. The samples
were obtained from the archives of Human Brain Tissue
Repository, Department of Neuropathology, NIMHANS,
Bangalore.
Protein extraction and normalization
Around 100 mg of frontal lobe brain tissue from each
individual were homogenized by crushing in liquid nitro-
gen with the aid of a mortar and pestle. Once the tissues
were ground to fine powder, around 1 ml of 0.5% SDS
was added and homogenized. Tissue lysate was trans-
ferred to sterile microcentrifuge tubes and centrifuged at
14,000 × g for 30 min at 4°C. Clear supernatant was col-
lected in separate microcentrifuge tubes. Total protein es-
timation was carried out using BCA protein assay (Pierce,
Thermo Scientific). Normalization of protein amounts
was confirmed using 10% SDS-PAGE. Equivalent amounts
of protein from each of the five TE with HIV-1 samples
were pooled and similar processing was done for control
samples.
iTRAQ labeling and strong cation exchange
chromatography
Pooled protein samples from each condition were reduced,
alkylated and digested with trypsin. iTRAQ labeling
(Applied Biosystems, cat# - 4352135) of peptides was
carried out according to manufacturer’s protocol as
described earlier [71]. Briefly, 200 μg of protein from each
condition was treated with 4 μl of reducing agent (tris
(2-carboxyethyl) phosphine) at 60°C for 1 hour and alkyl-
ation of cysteine residues was carried out by incubating
the samples with 2 μl of methyl methanosulfonate for
10 minutes at room temperature. Alkylated proteins were
then digested using sequencing grade trypsin (Promega,
cat# - V511A) with an enzyme to substrate ratio of 1:20
(w/w) at 37°C for 16 hours. Peptides from each condition
were split into two equal halves and iTRAQ labeling was
carried out in replicates. Peptides from control samples
was labeled using iTRAQ reagent yielding reporter ions114 and 115, peptides from TE with HIV-1 patient sam-
ples was labeled with iTRAQ reagents yielding reporter
ions 116 and 117. Labeling was carried out by incubating
the peptide-label mixture at room temperature for one
hour, the reaction was quenched by addition of 150 μl
milliQ water followed by incubation at room temperature
for one hour.
iTRAQ labeled peptides from control and TE with HIV-
1 were pooled, vacuum dried and reconstituted in 5 mM
potassium phosphate buffer, 25% acetonitrile (pH 2.8)
(solvent A). Strong cation exchange chromatography
was carried out as described earlier [72]. The peptides
were fractionated on polysulfoethyl A column (PolyLC,
Columbia, MD) (100 × 2.1 mm, 5 μm particles with 300 Å
pores) Agilent 1200 infinity series HPLC system for a
period of 50 minutes using a gradient of increasing salt
concentration of up to 350 mM KCl in solvent A. The
fractions collected were pooled based on SCX profile into
21 fractions, dried and reconstituted in 40 μl of 0.1% for-
mic acid. Samples were desalted using C18 (3 M Empore
high-performance extraction disks) stage tip dried and
stored in -20°C till mass spectrometric analysis.
LC-MS/MS analysis
LC-MS/MS analysis was carried out on LTQ Orbitrap Velos
ETD – mass spectrometer (Thermo Scientific, Bremen,
Germany) interfaced with Proxeon nanoLCII (Thermo
Scientific, Bremen, Germany). Peptides were analyzed
on a Reversed Phase Liquid Chromatography (RPLC).
The RPLC system equipped with a pre-column (2 cm,
5 μ – 100 Å) and an analytical column (12 cm, 3 μ –
100 Å) made with magic AQ C18 material (Michrom
Bioresources, Inc, Auburn, CA) packed in-house. Further,
the peptides are sprayed using 10 μ nano electro spray
emitter tip (New Objective, Woburn, MA) fixed to an NSI
source. The peptides were loaded on the pre column using
solvent A (0.1% formic acid, 5% acetonitrile and resolved
on the analytical column using a linear gradient of 8-30%
solvent B (95% acetonitrile, 0.1% formic acid) for 75 mi-
nutes at a constant flow rate of 0.35 μl/min. The spray
voltage and heated capillary temperature were set to
2.2 kV and 250°C, respectively. The MS spectra were
acquired in a data-dependent manner in the m/z range of
350 to 1800. From each MS survey scan, 15 most intense
precursor ions were selected for fragmentation. MS and
MS/MS scans were acquired in an Orbitrap mass analyzer
and the peptides were fragmented by higher energy colli-
sion dissociation with normalized collision energy of 41%.
MS scans were acquired at a resolution of 60,000 at
400 m/z, while MS/MS scans were acquired at a reso-
lution of 15,000. The automatic gain control (AGC) for
full FT MS was set to 1 million ions and for FT MS/MS
was set to 0.1 million ions with a maximum time of accu-
mulation of 200 ms and 500 ms, respectively.
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The mass spectrometry data obtained was searched against
the human RefSeq 52 proteins using Proteome Discoverer,
version 1.3.0.339 (Thermo Scientific, Bremen, Germany)
workflow. The workflow consisted of spectrum selector,
reporter ion quantifier and SEQUEST nodes along with
peptide validator node. Search parameters included trypsin
as the enzyme with 1 missed cleavage; oxidation of methio-
nine was set as dynamic modification, while methylthio
modification of cysteine and iTRAQ modification at
N-terminus of the peptide and lysine were set as static
modifications. Precursor and fragment mass tolerance
were set to 20 ppm and 0.1 Da, respectively with a
signal to noise ratio of 1.5 for a precursor mass range
of 350-10,000 Da. The raw data obtained was searched
against decoy database to calculate 1% false discovery
rate cut-off score. Spectra that matched to the contam-
inants and those that did not pass the 1% FDR thresh-
old were not considered for analysis.
Bioinformatics analysis
Bioinformatics analysis was carried out to categorize
proteins based on biological processes, cellular compo-
nent and molecular function using annotations in Human
Protein Reference Database (HPRD) [15,16], which is
in compliance with gene ontology (GO) standards. The
differentially expressed proteins having ≥1.5 fold change
were taken as input and biological network was generated
using Pathway Architect module of GeneSpring version
12.6 (Agilent Biosystems, Santa Clara, CA). We also inte-
grated the interaction data from NetPath (http://www.net-
path.org) and HPRD (http://www.hprd.org) in the analysis
using GeneSpring software as described earlier [17,72,73].
Immunohistochemical labeling
Validation of differentially expressed proteins in TE
co-infected with HIV-1 was carried out by immunohis-
tochemical staining for 15 toxoplasma encephalitis cases
and 6 controls using commercially available antibodies.
Formalin fixed and paraffin embedded autopsy tissues
were collected and cut into 5 μm thick sections on glass
slides. These slides were subjected for deparaffinization
and rehydration. Endogenous peroxidase activity was
quenched by 3% H2O2 for 20 min at room temperature.
Heat induced antigen retrieval was carried out using
pressure cooker by placing the tissue sections in citrate
buffer (pH 6.0). The tissue sections were incubated
with 3% skimmed milk in PBS, pH 7.4 at room temperature
followed by incubation with primary antibodies at following
dilutions – anti-major histocompatibility complex, class I,
B (dilution 1:200, cat # sc-55582, Santa Cruz), anti-alpha-1-
antitrypsin (dilution 1:2000, cat # HPA00927-100 μl,
Sigma-Aldrich), anti-rho-related GTP-binding protein
RhoG (dilution 1:50, cat # HPA039871-100UL, Sigma-Aldrich) for two hours at room temperature. In paral-
lel with test slides, appropriate negative and positive controls
were also subjected for incubation at room temperature,
followed by incubation with pre-diluted secondary antibody
conjugated with poly HRP (catalog # QD630-XAKE) from
BioGenex. The reaction was visualized with chromogen sub-
strate DAB/H2O2 as per manufacturer’s instructions. The
sections were counterstained with hematoxylin. The immu-
nolabeled sections were examined and staining pattern, in-
tensity, subcellular localization were visually scored by two
expert neuropathologists - AM and SKS (NIMHANS).
Data availability
We submitted the mass spectrometry data to Human
Proteinpedia to make it available to the public [13]. The
study design, experimental details, list of proteins and
peptides identified in the study can be accessed using
the following URL: http://www.humanproteinpedia.org/
data_display?exp_id=00707. The mass spectrometry pro-
teomics data have also been deposited to the Proteo-
meXchange Consortium [14] via the PRIDE partner
repository with the dataset identifier PXD000261.
Additional files
Additional file 1: Table S1. A complete list of proteins along with
peptides identified from toxoplasma encephalitis and control brain
tissues.
Additional file 2: Table S2. Details of samples used for quantitative
proteomic analysis of toxoplasma encephalitis. Table S3. Details of
samples used for immunohistochemistry-based validation of differentially
expressed molecules from quantitative proteomic analysis of toxoplasma
encephalitis co-infected with HIV.
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